vTv Therapeutics Q3 EPS $(0.02), Same YoY

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 9, 2021

1 minute read

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

Recap: Eneti Q2 Earnings

By Benzinga Insights

Today, 6:20 PM

Shares of Eneti (NYSE:NETI) rose 0.1% after the company reported Q2 results. Quarterly Results Earnings per share rose 115.85% year over year to $0.90, which beat the estimate of $0.21.

NETI

News

Ansys Reports Extension Of Collab With BMW ‘to create the first-ever end-to-end tool chain specifically guided by safety principles to develop and validate ADAS and automated/autonomous driving functions,’ No Terms Disclosed

By Benzinga Newsdesk

Today, 6:20 PM

The BMW Group and Ansys join forces to implement unique simulation capabilities leading to more reliability in automated/autonomous vehicle technology / Key Highlights The BMW Group extends its collaboration with

ANSS

Credit Suisse Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $100

By Benzinga Newsdesk

Today, 6:20 PM

Credit Suisse initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Outperform rating and announces Price Target of $100.

NTLA

PFSweb Announces Updated Ex-Dividend Date For Special Dividend Will Be December 16 In Lieu Of The November 30 Date Previously Announced

By Benzinga Newsdesk

Today, 6:20 PM

PFSweb, Inc. (NASDAQ:PFSW) (the "Company") today announced that, in connection with the Company's recently announced special cash dividend of $4.50 per share (the "Special Dividend"),

PFSW

vTv Therapeutics Q3 EPS $(0.02), Same YoY

Related Posts

Recap: Eneti Q2 Earnings

Ansys Reports Extension Of Collab With BMW ‘to create the first-ever end-to-end tool chain specifically guided by safety principles to develop and validate ADAS and automated/autonomous driving functions,’ No Terms Disclosed

Credit Suisse Initiates Coverage On Intellia Therapeutics with Outperform Rating, Announces Price Target of $100

PFSweb Announces Updated Ex-Dividend Date For Special Dividend Will Be December 16 In Lieu Of The November 30 Date Previously Announced